Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

2.

Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure.

Wong FL, Bhatia S, Landier W, Francisco L, Leisenring W, Hudson MM, Armstrong GT, Mertens A, Stovall M, Robison LL, Lyman GH, Lipshultz SE, Armenian SH.

Ann Intern Med. 2014 May 20;160(10):672-83. doi: 10.7326/M13-2498.

3.

Cost-effectiveness of screening for asymptomatic left ventricular dysfunction in childhood cancer survivors.

Steingart RM, Liu JE, Oeffinger KC.

Ann Intern Med. 2014 May 20;160(10):731-2. doi: 10.7326/M14-0823. No abstract available.

PMID:
24842420
4.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

5.

The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy.

Nordmann AJ, Krahn M, Logan AG, Naglie G, Detsky AS.

Pharmacoeconomics. 2003;21(8):573-85.

PMID:
12751915
6.

Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction.

Sandhu AT, Ollendorf DA, Chapman RH, Pearson SD, Heidenreich PA.

Ann Intern Med. 2016 Nov 15;165(10):681-689. doi: 10.7326/M16-0057. Epub 2016 Aug 30.

PMID:
27571284
8.

Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer.

Lipshultz SE, Lipsitz SR, Sallan SE, Simbre VC 2nd, Shaikh SL, Mone SM, Gelber RD, Colan SD.

J Clin Oncol. 2002 Dec 1;20(23):4517-22.

PMID:
12454107
9.

Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.

Zhang Z, Mahoney EM, Kolm P, Spertus J, Caro J, Willke R, Weintraub WS.

Am J Cardiovasc Drugs. 2010;10(1):55-63. doi: 10.2165/11319940-000000000-00000.

PMID:
20104935
10.

Health and economic benefits of increased beta-blocker use following myocardial infarction.

Phillips KA, Shlipak MG, Coxson P, Heidenreich PA, Hunink MG, Goldman PA, Williams LW, Weinstein MC, Goldman L.

JAMA. 2000 Dec 6;284(21):2748-54.

PMID:
11105180
11.

A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.

McKenna C, Burch J, Suekarran S, Walker S, Bakhai A, Witte K, Harden M, Wright K, Woolacott N, Lorgelly P, Fenwick L, Palmer S.

Health Technol Assess. 2010 May;14(24):1-162. doi: 10.3310/hta14240. Review.

12.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

13.

Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation.

Colquitt JL, Mendes D, Clegg AJ, Harris P, Cooper K, Picot J, Bryant J.

Health Technol Assess. 2014 Aug;18(56):1-560. doi: 10.3310/hta18560. Review.

14.

Cost-effectiveness of diagnostic strategies for patients with chest pain.

Kuntz KM, Fleischmann KE, Hunink MG, Douglas PS.

Ann Intern Med. 1999 May 4;130(9):709-18.

PMID:
10357689
15.

The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.

Golan L, Birkmeyer JD, Welch HG.

Ann Intern Med. 1999 Nov 2;131(9):660-7.

PMID:
10577328
16.

Incremental cost-effectiveness of guideline-directed medical therapies for heart failure.

Banka G, Heidenreich PA, Fonarow GC.

J Am Coll Cardiol. 2013 Apr 2;61(13):1440-6. doi: 10.1016/j.jacc.2012.12.022. Epub 2013 Feb 20.

17.

Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction.

Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA, Stevenson LW, Shekelle PG.

J Am Coll Cardiol. 2004 Mar 17;43(6):1019-26.

18.

Treatment with angiotensin converting enzyme inhibitors, angiotensin-II-antagonists and beta-blockers in an unselected group of patients with chronic heart failure.

Watz R, Ekstrand AB, Engelbrektson V, Beermann B.

Eur J Clin Pharmacol. 2005 May;61(3):209-14. Epub 2005 Mar 11.

PMID:
15761755
19.

Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction).

Linde C, Mealing S, Hawkins N, Eaton J, Brown B, Daubert JC; REVERSE study group..

Eur Heart J. 2011 Jul;32(13):1631-9. doi: 10.1093/eurheartj/ehq408. Epub 2010 Nov 25.

PMID:
21112898
20.

Supplemental Content

Support Center